BioCentury
ARTICLE | Company News

Affitech cancer news

March 19, 2012 7:00 AM UTC

Affitech said its board unanimously recommended that shareholders accept a voluntary conditional offer from shareholder Trans Nova Investments Ltd. to purchase the 59.99% of Affitech it does not own for DKK0.20 per share, or DKK58.5 million ($10.6 million), based on 487.7 million shares outstanding on Feb. 28. The price is a 67% premium to Affitech's close of DKK0.12 on Feb. 27, the day before the offer was announced. The offering period expires March 27 (see BioCentury, March 3). ...